Gain Therapeutics Inc.
Last updated September 27, 2026
Organization details
- Legal name
- Gain Therapeutics Inc.
- Ownership
- Public
- Status
- Active
- Headquarters country
- United States
- Ticker symbol
- GANX
- Primary stock exchange
- Nasdaq
Identifiers
- SEC CIK
- 0001819411
Board of directors
-
Claude Nicaise · DirectorSince 2023
-
Dov A. Goldstein M.D. · DirectorSince 2023
-
Eric I. Richman · DirectorSince 2023
-
Gene Mack · Director · CEO, PresidentSince 2025
-
Gwen A. Melincoff · DirectorSince 2023
-
Hans Peter Hasler · DirectorSince 2023
-
Jeffrey Scott Riley · DirectorSince 2023
-
Khalid Islam · Director · Executive ChairmanSince 2023
-
Matthias Alder · Director · Chief Executive OfficerSince 2023
Chief executives
Matthias Alder
· Chief Executive Officer
Dates unknown
Gene Mack
· CEO, President
Dates unknown
Board connections
5 of this board's directors also sit on 8 other boards.
- via Claude Nicaise
- via Gwen A. Melincoff
- via Dov A. Goldstein M.D.
- via Khalid Islam
- via Claude Nicaise
- via Hans Peter Hasler
- via Gwen A. Melincoff
- via Claude Nicaise
Insider trades
All notable trades →From SEC Forms 4 and 5. Open-market purchases and sales are highlighted; grants, option exercises and shares withheld for tax are routine.
- Bought, last 12 months
- $0
- 0 purchases by 0 insiders
- Sold, last 12 months
- $0
- 0 sales by 0 insiders
| Date | Insider | Transaction | Shares | Price | Value |
|---|---|---|---|---|---|
| Aug 9, 2024 | Khalid Islam Director, Officer (Executive Chairman) | Open-market purchase | +50,000 | $1.00 | $50,000 |
| Aug 9, 2024 | Mack Gene Officer (CFO and Interim CEO) | Open-market purchase | +14,400 | $1.01 | $14,544 |
| Jul 1, 2024 | Eric I. Richman Director | Open-market purchase | +5,000 | $1.23 | $6,150 |
| Jul 1, 2024 | Eric I. Richman Director | Open-market purchase | +12,000 | $1.21 | $14,520 |
| Mar 28, 2024 | Jeffrey Scott Riley Director | Open-market purchase | +30,000 | $3.86 | $115,800 |
| Mar 26, 2024 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +18,750 | — | — |
| Mar 26, 2024 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +825 | — | — |
| Mar 26, 2024 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +637 | — | — |
| Mar 26, 2024 | Matthias Alder Director, Officer (Chief Executive Officer) | Shares withheld for tax | −6,085 | $4.06 | $24,705 |
| Dec 21, 2023 | Matthias Alder Director, Officer (Chief Executive Officer) | Open-market sale | −206 | $2.46 | $507 |
| Dec 20, 2023 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +637 | — | — |
| Dec 7, 2023 | Matthias Alder Director, Officer (Chief Executive Officer) | Open-market sale | −1,820 | $2.50 | $4,550 |
| Oct 1, 2023 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +825 | — | — |
| Sep 20, 2023 | Eric I. Richman Director | Option exercise | +54,900 | — | — |
| Sep 20, 2023 | Matthias Alder Director, Officer (Chief Executive Officer) | Option exercise | +2,550 | — | — |
Reviews (0)
Sign in to write a review.
No reviews yet. Be the first to write one.